Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome

  • Ronald H. Goldschmidt


Care for patients with human immunodeficiency virus (HIV) infection requires excellence in all aspects of family practice. The family physician’s roles are many: providing patient education to prevent uninfected persons from becoming infected; identifying and instituting early intervention for infected persons; delivering comprehensive care of symptomatic disease including the acquired immunodeficiency syndrome (AIDS); and providing support and care for the family. This broad scope of clinical responsibilities is in an area of clinical medicine where the knowledge base and management strategies are evolving rapidly. New manifestations of HIV disease, diagnostic protocols, and drug recommendations (Table 36.2)1 change on a regular basis. Epidemiologic, social, and community trends also continue to have important effects on clinical care. This chapter provides an overview of important clinical aspects of HIV disease for the family physician.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Tuberculin Skin Test Acquire Immunodeficiency Syndrome Pneumocystis Carinii Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions: 1993. J Am Board Fam Pract 1993;6:297–315.PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control; Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36 Suppl 1:1S-15S.Google Scholar
  3. 3.
    Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989;38 Suppl 6:1–37.Google Scholar
  4. 4.
    Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39 (No. RR-1): 1–14.Google Scholar
  5. 5.
    Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR 1987;36:509–15.Google Scholar
  6. 6.
    Goldschmidt RH, Legg JJ. Counseling patients about HIV test results. J Am Board Fam Pract 1991;4:361–3.PubMedGoogle Scholar
  7. 7.
    Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989;38:236–8, 243–50.Google Scholar
  8. 8.
    Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991;40(No. RR-5):27–33.Google Scholar
  9. 9.
    Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double blind, placebo-controlled trial. Ann Intern Med 1990;112:727–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323: 1009–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Lambert JS, Seidlin M, Reichman RC, et al. 2′, 3′-Dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase 1 trial. N Engl J Med 1990;322: 1333–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase 1 trial. N Engl J Med 1990;322:1340–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992;116:13–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992;41(No. RR-4):1–11.Google Scholar
  16. 16.
    Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108:585–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Horsburgh Jr CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324: 1332–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes PF, Bloch AB, Davidson PT, Snider Jr DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991;324:1644–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Berger TG, Obuch ML, Goldschmidt RH. Dermatologic manifestations of HIV infection. Am Fam Physician 1990;41:1729–42.PubMedGoogle Scholar
  20. 20.
    Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Am Rev Respir Dis 1990; 141: 1356–72, 1582–98.PubMedCrossRefGoogle Scholar
  22. 22.
    Goldschmidt RH. Recommendations for the treatment of acute Pneumocystis carinii pneumonia. J Am Board Fam Pract 1991;4: 58–60.PubMedGoogle Scholar
  23. 23.
    National Institutes of Health—University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis carinii Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:1500–4.CrossRefGoogle Scholar
  24. 24.
    Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989;86:539–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Spence MR, Reboli AC. Human immunodeficiency virus infection in women. Ann Intern Med 1991;115:827–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83–89.PubMedCrossRefGoogle Scholar
  27. 27.
    Falloon J, Eddy J, Wiener L, Pizzo PA. Human immunodeficiency virus infection in children. J Pediatr 1989;114:1–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Ronald H. Goldschmidt

There are no affiliations available

Personalised recommendations